26th Jan 2015 14:44
LONDON (Alliance News) - GlaxoSmithKline PLC announced the simultaneous availability of two of its recently approved products for the treatment of asthma and COPD to retail pharmacies in the US.
Arnuity Ellipta (fluticasone furoate inhalation powder) is a once-daily inhaled corticosteroid (ICS) medicine for the maintenance treatment of asthma. It is the first product in the Ellipta inhaler for the treatment of asthma to be introduced in the US. Arnuity Ellipta is indicated for once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.
The company also announced that Incruse Ellipta (umeclidinium bromide), an anticholinergic indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, is now available to retail pharmacies in the US. Incruse is GSK's first anticholinergic monotherapy, a type of bronchodilator that can relax airway smooth muscles and improve airflow in and out of the lungs.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline